Managing chemotherapy-induced nausea and vomiting

E. A. Perez

Research output: Contribution to journalArticle

Abstract

The 5-HT3-receptor antagonists (granisetron, ondansetron) play a prominent role in the management of nausea and vomiting caused by chemotherapeutic agents. Their use is considered appropriate in patients receiving chemotherapy with high or moderately high emetogenic potential. Using these drugs at their lowest effective dose helps reduce their cost. Trials comparing granisetron with ondansetron generally indicate that a single intravenous (IV) dose of granisetron is as effective as multiple or single doses of IV ondansetron. Both drugs are well tolerated. The addition of dexamethasone can enhance the benefits of 5-HT3-receptor antagonist therapy.

Original languageEnglish (US)
JournalP and T
Volume21
Issue number3 SUPPL.
StatePublished - 1996

Fingerprint

Granisetron
Ondansetron
Nausea
Serotonin 5-HT3 Receptor Antagonists
Vomiting
Receptors, Serotonin, 5-HT3
Drug Therapy
Pharmaceutical Preparations
Dexamethasone
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Perez, E. A. (1996). Managing chemotherapy-induced nausea and vomiting. P and T, 21(3 SUPPL.).

Managing chemotherapy-induced nausea and vomiting. / Perez, E. A.

In: P and T, Vol. 21, No. 3 SUPPL., 1996.

Research output: Contribution to journalArticle

Perez, EA 1996, 'Managing chemotherapy-induced nausea and vomiting', P and T, vol. 21, no. 3 SUPPL..
Perez, E. A. / Managing chemotherapy-induced nausea and vomiting. In: P and T. 1996 ; Vol. 21, No. 3 SUPPL.
@article{3eec32936a5442ba93861b5a0802daad,
title = "Managing chemotherapy-induced nausea and vomiting",
abstract = "The 5-HT3-receptor antagonists (granisetron, ondansetron) play a prominent role in the management of nausea and vomiting caused by chemotherapeutic agents. Their use is considered appropriate in patients receiving chemotherapy with high or moderately high emetogenic potential. Using these drugs at their lowest effective dose helps reduce their cost. Trials comparing granisetron with ondansetron generally indicate that a single intravenous (IV) dose of granisetron is as effective as multiple or single doses of IV ondansetron. Both drugs are well tolerated. The addition of dexamethasone can enhance the benefits of 5-HT3-receptor antagonist therapy.",
author = "Perez, {E. A.}",
year = "1996",
language = "English (US)",
volume = "21",
journal = "P and T",
issn = "1052-1372",
publisher = "MediMedia USA Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Managing chemotherapy-induced nausea and vomiting

AU - Perez, E. A.

PY - 1996

Y1 - 1996

N2 - The 5-HT3-receptor antagonists (granisetron, ondansetron) play a prominent role in the management of nausea and vomiting caused by chemotherapeutic agents. Their use is considered appropriate in patients receiving chemotherapy with high or moderately high emetogenic potential. Using these drugs at their lowest effective dose helps reduce their cost. Trials comparing granisetron with ondansetron generally indicate that a single intravenous (IV) dose of granisetron is as effective as multiple or single doses of IV ondansetron. Both drugs are well tolerated. The addition of dexamethasone can enhance the benefits of 5-HT3-receptor antagonist therapy.

AB - The 5-HT3-receptor antagonists (granisetron, ondansetron) play a prominent role in the management of nausea and vomiting caused by chemotherapeutic agents. Their use is considered appropriate in patients receiving chemotherapy with high or moderately high emetogenic potential. Using these drugs at their lowest effective dose helps reduce their cost. Trials comparing granisetron with ondansetron generally indicate that a single intravenous (IV) dose of granisetron is as effective as multiple or single doses of IV ondansetron. Both drugs are well tolerated. The addition of dexamethasone can enhance the benefits of 5-HT3-receptor antagonist therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029876914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029876914&partnerID=8YFLogxK

M3 - Article

VL - 21

JO - P and T

JF - P and T

SN - 1052-1372

IS - 3 SUPPL.

ER -